Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Fisher Underscores Allergy Test Opportunity With $3.5 Bil. Phadia Deal

This article was originally published in The Gray Sheet

Executive Summary

Thermo Fisher Scientific wants to claim a dominant share of the budding in vitro allergy testing market segment in the U.S. with its planned $3.5 billion acquisition of Swedish firm Phadia, announced May 19.
Advertisement

Related Content

Thermo Fisher To Dominate Transplant Dx Market With $925 Million One Lambda Purchase
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011
People In Brief
People In Brief
Advertisement
UsernamePublicRestriction

Register

MT030180

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel